Acute myeloblastic leukemia following prolonged treatment of crohn's disease with 6-mercaptopurine

Digestive Diseases and Sciences

Volumn 43, Issue 8, 1998, Pages 1791-1793

  Heizer, William D ^a   Peterson, John L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

6 mercaptopurine; Crohn's disease; Immunosuppression; Leukemia; Malignancy

Indexed keywords

AZATHIOPRINE; CEFALEXIN; CIPROFLOXACIN; FERROUS SULFATE; MERCAPTOPURINE; METRONIDAZOLE; PREDNISONE; SALAZOSULFAPYRIDINE; ZINC SULFATE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER RISK; CASE REPORT; CHROMOSOME 7; CHROMOSOME DELETION; CLINICAL FEATURE; CROHN DISEASE; CYTOGENETICS; DISEASE COURSE; DRUG INDUCED DISEASE; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PANCYTOPENIA; PRIORITY JOURNAL;

EID: 0031827275     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018896006155     Document Type: Article

References (16)

1. Stenson WF: Inflammatory bowel disease. In Textbook of Gastroenterology. T. Yamada (ed). Philadelphia, JB Lippincott, 1995, pp 1781-1782
2. Elton E, Hanauer SB: The medical management of Crohn's disease. Aliment Pharmacol Ther 10:1-22, 1996
3. Korelitz RI, Adler DJ, Mendelsohn RA, Sacknoff AL: Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease. Am J Gastroenterol 88:1198-1205, 1993
4. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lenard-Jones JE: Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 343:1259-1252, 1994
5. Present DH, Meltzer SJ, Krumholz MF, Wolke A, Korelitz BI: 6-Mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity. Ann Intern Med 111:641-649, 1989
6. Forbes A, Reading G: The risks of malignancy from either immunosuppression or diagnostic radiation in inflammatory bowel disease. Aliment Pharmacol Ther 9:465-470, 1995
7. Korelitz RI, Fleisher MR, Burns AWR, Grand T, Salknoff A: Should toxicity to 6MP serve to discourage long term maintenance therapy of IBD? Experience of the last quarter century. Presented at American College of Gastroenterology Meeting, Seattle, Washington, October 1996. Indexed in Am J Gastroenterol 91:1996 but Abstract omitted due to printing error. See Gastroenterology and Endoscopy News, February, 1996, pp 620-621
8. Korelitz RI, Fleisher MR, Burns AWR, Grand T, Salknoff A: Should toxicity to 6MP serve to discourage long term maintenance therapy of IBD? Experience of the last quarter century. Presented at American College of Gastroenterology Meeting, Seattle, Washington, October 1996. Indexed in Am J Gastroenterol 91:1996 but Abstract omitted due to printing error. See Gastroenterology and Endoscopy News, February, 1996, pp 620-621
9. Korelitz RI, Fleisher MR, Burns AWR, Grand T, Salknoff A: Should toxicity to 6MP serve to discourage long term maintenance therapy of IBD? Experience of the last quarter century. Presented at American College of Gastroenterology Meeting, Seattle, Washington, October 1996. Indexed in Am J Gastroenterol 91:1996 but Abstract omitted due to printing error. See Gastroenterology and Endoscopy News, February, 1996, pp 620-621
10. Grunwald HW, Rosner F: Acute leukemia and immunosuppressive drug use. A review of patients undergoing immunosuppressive therapy for nonneoplastic diseases. Arch Intern Med 139:451, 1979
11. Mitelman F, Nilsson PG, Brandt L, Alimena G, Gastaldi R, Dallapiccola B: Chromosome pattern, occupation and clinical features in patients with acute nonlymphocytic leukemia. Cancer Genet Cytogenet 4:197-214, 1981
12. Le Beau MM, Albain KS, Larson RA, Vardiman JW, Davis EM, Blough RR, Golomb HM, Rowley JD: Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol 4:325-345, 1986
13. Kantarjian HM, Keating MJ, Walters RS, Smith T, Cork A, McCredie KB, Freireich EJ: Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol 4:1748-1757, 1986
14. Iurlo A, Mecucci C, Van Orshoven A, Michaux J-L, Boogaerts M, Noens L, Bosly A, Louwagie A, Van Den Berghe H: Cytogenetic and clinical investigations in 76 cases with therapy-related leukemia and myelodysplastic syndrome. Cancer Genet Cytogenet 43:227-241, 1989
15. Levine EG, Bloomfield CD: Leukemias and myelodysplastic syndromes secondary to drug, radiation and environmental exposure. Semin Oncol 19:47-84, 1992
16. Caspi O, Polliack A, Klar R, Ben-Yehuda D: The association of inflammatory bowel disease and leukemia - coincidence or not? Leuk Lymphoma 17:255-262, 1995